文献速递肾癌与肾肿瘤

临床T1肾细胞癌部分肾切除后偶然病理T3a升期的多机构生存分析

Multi-institutional Survival Analysis of Incidental Pathologic T3a Upstaging in Clinical T1 Renal Cell Carcinoma Following Partial Nephrectomy.
PubMed 文献 · Urology · 2018-04-17

多机构回顾性分析1995–2015年1955例临床T1行部分肾切除患者,95例病理升期至pT3a,按1:2匹配pT1a-b对照。癌症特异性生存率也更低。

要点

  • 临床T1部分肾切除后病理升期pT3a者无复发生存率显著低于pT1a-b。

核心结论

  • 部分肾切除后偶然病理升期至pT3a的患者,其无复发生存率和癌症特异性生存率显著低于pT1a-b患者。

研究设计与样本

  • 密歇根大学与Moffitt癌症中心1995–2015年回顾性队列,共1955例临床T1行部分肾切除患者,其中95例病理升期pT3a。
  • pT3a患者按临床病理特征与pT1a-b患者1:2匹配,中位随访38.2个月。
  • 采用Kaplan-Meier分析及单因素、多因素Cox比例风险回归,主要终点为无复发生存率。

主要发现

  • pT3a患者中,人口学或病理特征与肾细胞癌复发无关联(单因素及多因素分析)。

临床怎么用

  • 部分肾切除后病理升期pT3a提示复发和死亡风险增高,应加强术后随访与复发监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate whether incidental pathologic T3a (pT3a) upstaging after partial nephrectomy (PN) for clinical T1 disease results in inferior oncologic outcomes compared to pT1a-b disease. MATERIALS AND METHODS: Retrospective chart review was completed at the University of Michigan and Moffitt Cancer Center to identify patients undergoing PN for clinical T1 masses between 1995 and 2015. A total of 1955 patients were identified, of which 95 had pT3a upstaging. Median follow-up was 38.2 months. Patients with pT3a disease were individually matched by clinicopathologic features with patients undergoing PN with pT1a-b disease in a 1:2 ratio. Kaplan-Meier analysis and univariate and multivariable Cox proportional hazards regression analysis were performed. Primary endpoint was recurrence-free survival (RFS). Secondary endpoints were all-cause mortality, cancer-specific survival (CSS), and rates of local and distant recurrence. RESULTS: Recurrence rates were significantly higher in pT3a disease compared to pT1a-b controls (P <.01). In those patients with pT3a upstaging, 3- and 5-year RFS were 81% and 58%, compared to 86% and 75% in pT1a-b controls (P = .01). CSS at 3 and 5 years were 91% and 90% in pT3a disease and 100% and 97% in pT1a-b controls (P <.01). All-cause mortality at 3 and 5 years were 82% and 71% in pT3a disease and 93% and 80% in pT1a-b controls (P = .04). Univariate and multivariable analysis of pT3a disease demonstrated no association between demographic or pathologic characteristics and RCC recurrence. CONCLUSION: Patients with pT3a upstaging following PN experience a significantly reduced RFS and CSS when compared to pT1 disease.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Russell CM, Lebastchi AH, Chipollini J, et al. Multi-institutional Survival Analysis of Incidental Pathologic T3a Upstaging in Clinical T1 Renal Cell Carcinoma Following Partial Nephrectomy. Urology. 2018. PMID: 29678662. doi:10.1016/j.urology.2018.04.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。